Serum MicroRNAs as Diagnostic Biomarkers of Colorectal Cancer

Launched by BISHOY SHEHATA · Dec 12, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the potential of certain tiny molecules called microRNAs to help diagnose colorectal cancer (CRC). Specifically, researchers are looking at how levels of microRNAs, like miR-15b and miR-21, differ in people with colorectal cancer compared to healthy individuals. The goal is to see if these microRNAs can be used as reliable markers (indicators) for diagnosing the disease.

To be eligible for the trial, participants need to be adults aged 18 to 75 who have been diagnosed with primary colorectal cancer and have not yet received any treatment, such as chemotherapy or radiation. The study will also include healthy volunteers who do not have any colorectal disease for comparison. If you decide to participate, you will help researchers better understand the role of these microRNAs in diagnosing colorectal cancer, which could lead to improved detection methods in the future. It's important to note that the trial is not yet recruiting participants, so you'll need to keep an eye out for when it begins.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults (age 18-75) diagnosed with primary CRC (histopathologically confirmed).
• • CRC patients who have not received prior treatment (i.e., chemotherapy or radiation).
• • Age-matched healthy controls without colorectal disease
• Exclusion Criteria:
• • Patients with secondary tumors or metastasis originating from non-colorectal sources.
• • Patients with prior history of CRC.
• • Patients who refuse to contribute in this study.